Financial Post EN

Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications

SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the new drug applications (the “NDAs”) for the company’s product, toripalimab injection (subcutaneous injection [code: JS001sc]), for 12 indications in […]

Mar 09, 2026 &03030909202631; 13:03 UTC financialpost.com Trending 2/5

Read original on financialpost.com ↗

↗

Positive for markets

Sentiment score: +75/100

High impact Medium-term (weeks)

WHAT THIS MEANS

Junshi Biosciences received NMPA acceptance of new drug applications for toripalimab injection (subcutaneous) across 12 indications, representing significant regulatory progress for this immunotherapy candidate. This multi-indication approval pathway could substantially expand the drug's commercial potential and market addressable size in China.

AI CONFIDENCE

85% Very high

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

1877.HK

1877.HKStock

Expected to rise

Regulatory milestone for toripalimab across 12 indications increases probability of commercialization and revenue diversification

↑

688180.SS

688180.SSStock

Expected to rise

Shanghai listing benefits from positive NMPA regulatory progress on domestic biopharmaceutical asset

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Long positions on Junshi Biosciences (1877.HK, 688180.SS) are warranted given the significant regulatory de-risking and multi-indication approval pathway. Monitor upcoming clinical trial data and NMPA approval timelines for potential catalysts.

KEY SIGNALS

NMPA regulatory acceptance across multiple indicationsExpanded addressable market for toripalimabImmunotherapy pipeline advancementChina domestic pharmaceutical approval progressReduced regulatory risk for multi-indication drug

SECTORS INVOLVED

BiotechnologyPharmaceuticalsHealthcare

Analysis generated on Mar 09, 2026 at 13:18 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Financial Post. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications

RELATED INTELLIGENCE